Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Core Insights - Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies [3] - The company will present at the Guggenheim Annual Healthcare Innovation Conference from November 10-12, 2025, in Boston, MA [1][2] Presentation Details - The presentation will be in a fireside chat format featuring Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer [2] - Scheduled date and time for the presentation is November 10, 2025, at 4:00 p.m. ET [2] - A live and archived webcast of the presentation will be available on the company's investor relations webpage [2] Company Overview - Tenax Therapeutics owns global rights to develop and commercialize levosimendan, targeting the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension [3] - Currently, there are no approved products for PH-HFpEF, highlighting a significant market opportunity for the company [3] - The company's common stock is listed on The Nasdaq Stock Market under the symbol "TENX" [3]